Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Recurrent/Metastatic Triple Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07533123
What this trial is testing

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Who this might be right for
Triple Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 364
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Testing effectiveness (Phase 2)Ended earlyNCT01745367
What this trial is testing

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
AVEO Pharmaceuticals, Inc. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07487519
What this trial is testing

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Shanghai Henlius Biotech 180
Testing effectiveness (Phase 2)Looking for participantsNCT06799065
What this trial is testing

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Who this might be right for
Advanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+4 more
Accent Therapeutics 218
Testing effectiveness (Phase 2)UnknownNCT03044730
What this trial is testing

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+7 more
Northwestern University 30